Raymond James Financial
ELDN icon

Raymond James Financial’s Eledon Pharmaceuticals ELDN Stock Holding History

Raymond James Financial’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$140K Buy
35,413
+21,436
+153% +$77.9K ﹤0.01% 5127
2026
Q1 		$43K Buy
13,977
+3,377
+32% +$7.95K ﹤0.01% 5136
2025
Q4 		$16K Buy
+10,600
New +$25.2K ﹤0.01% 5107
2025
Q3 		– Sell
-600
Closed -$1.63K – 5496
2025
Q2 		$1.63K Buy
+600
New +$1.8K ﹤0.01% 6458

Other funds holding ELDN

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $60.8B AUM 42.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CCM
Catalio Capital Management New York $532M AUM 171.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
ZP
Zimmer Partners New York $4.34B AUM 22.78% 1-Year Est. Return

Raymond James Financial's ELDN Position: Q2 2026 in Review

Raymond James Financial increased its Eledon Pharmaceuticals (ELDN) stake by 153% in Q2 2026, buying an estimated $77.9K and bringing the position to 35,413 shares worth $140K. The position accounts for ﹤0.01% of the portfolio, ranked #5127.

Raymond James Financial first reported a position in ELDN in Q2 2025 and has held it in 4 quarters since. 161 funds tracked by Wall St. Rank hold ELDN as of Q2 2026.

  • Raymond James Financial held 35,413 shares of Eledon Pharmaceuticals worth $140K as of Q2 2026.
  • Raymond James Financial bought 21,436 Eledon Pharmaceuticals shares in Q2 2026, an estimated $77.9K.
  • Eledon Pharmaceuticals made up ﹤0.01% of Raymond James Financial's portfolio in Q2 2026, its #5127 holding.
  • Raymond James Financial first reported a position in Eledon Pharmaceuticals in Q2 2025 and has held it in 4 quarters since.
  • 161 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.